Dana-Farber Cancer Institute
Boston, MA
Accepting patients
NAUTIKA1
NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
- Phase 2
Accepting patients
CARE Study
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
- Has results
Accepting patients
Larotrectinib
A Pilot and Surgical Study of Larotrectinib for Treatment of Children With Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Tyrosine Kinase (TK) Inhibitor
- Phase 1
Accepting patients
LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers
- Observational Trial